Targets › MTOR
11 programs from 11 companies in 29 trials: 14 Phase 2, 11 Phase 1, 4 Phase 3; Oncology, Cardiovascular, Infectious disease; next expected readout Dec 2026.
Serine/threonine protein kinase which is a central regulator of cellular metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals. MTOR directly or indirectly regulates the phosphorylation of at least 800 proteins. (UniProt, P42345)
Open in Phaseline: the race on MTOR, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Celcuity | Gedatolisib Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor | MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CA | Phase 3 | Breast Cancer; mCRPC (Metastatic Castration-resistant Prostate Cancer); Endometrial Cancer; TNBC - Triple-Negative Breast Cancer | Dec 2026 |
| iVascular S.L.U. | Angiolite Sirolimus-eluting stent with thin-strut cobalt-chromium, open-cell design, durable biostab | MTOR | Phase 3 | Coronary Artery Disease | Jan 2027 |
| Palvella Therapeutics | QTORIN 3.9% Rapamycin Anhydrous Gel mTOR inhibitor | MTOR | Phase 3 | Microcystic Lymphatic Malformation | – |
| Supernus Pharmaceuticals | SPN-821 selective, direct enhancer of mTORC1 cellular signaling | MTOR | Phase 2 | Major Depressive Disorder (MDD) | Dec 2026 |
| Theodore S. Johnson | Indoximod mTORC1 activator | MTOR, RPTOR, MLST8 | Phase 2 | Glioblastoma; Ependymoma | Dec 2027 |
| David Reardon, MD | CC-115 mTOR and ATM kinase inhibitor | MTOR, ATM | Phase 2 | Glioblastoma | Feb 2028 |
| Faeth Therapeutics | Sapanisertib Serine/threonine-protein kinase mTOR inhibitor | MTOR | Phase 2 | Endometrial Cancer; HR+ HER2- Breast Cancer; Locally Advanced Bladder Urothelial Carcinoma; Advanced Lymphoma … | Sep 2028 |
| Restorbio | Dactolisib (BEZ235) Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor | MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CA | Phase 2 | Respiratory Tract Infections; Covid19 | – |
| AstraZeneca | Vistusertib Serine/threonine-protein kinase mTOR inhibitor | MTOR | Phase 2 | Non-Small Cell Lung Cancer; Meningioma; Metastatic Breast Cancer; BRCA1 Mutation Carrier | – |
| Eli Lilly | Samotolisib (LY3023414) Serine/threonine-protein kinase mTOR inhibitor; PI3-kinase class I inhibitor | MTOR, PIK3R1, PIK3CB, PIK3CG, PIK3CA | Phase 1 | Breast Neoplasms; Endometrial Cancer | Dec 2026 |
| SAPU NANO (US) | Sapu003 mTOR inhibitor | MTOR | Phase 1 | Breast Cancer Metastatic | Dec 2026 |
Endometrial Cancer (3) Advanced Lymphoma (2) Glioblastoma (2) Breast Cancer (2) Coronary Artery Disease (1) Respiratory Tract Infections (1) Covid19 (1) HR+ HER2- Breast Cancer (1) Locally Advanced Bladder Urothelial Carcinoma (1) Adult Glioblastoma (1) Leptomeningeal Neoplasm (1) Metastatic Lung Non-Small Cell Carcinoma (1)
small molecule (9), mixed (2)
iVascular S.L.U. (1) Restorbio (1) Faeth Therapeutics (1) Theodore S. Johnson (1) Celcuity (1) Palvella Therapeutics (1) Supernus Pharmaceuticals (1) SAPU NANO (US) (1) David Reardon, MD (1) Eli Lilly (1) AstraZeneca (1)
PIK3R1 (3) PIK3CB (3) PIK3CG (3) PIK3CA (3) RPTOR (1) MLST8 (1) ATM (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.